Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - powder for suspension - fluconazole 50 mg / 5 ml - fluconazole - fluconazole - fluconazole is indicated in the following fungal infections.fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis.• coccidioidomycosis.• invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.• vaginal candidiasis, acute or recurrent; when local therapy is not appropriate.• candidal balanitis when local therapy is not appropriate.• dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated.• tinea unguinium (onychomycosis) when other agents are not considered appropriate.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• to reduce the incidence of recurrent vaginal candidiasis (4 or more episodes a year).• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation).fluconazole is indicated in term newborn infants, infants, toddlers, children, and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - fluconazole is indicated in the following fungal infections .fluconazole is indicated in adults for the treatment of:• cryptococcal meningitis .• coccidioidomycosis . invasive candidiasis.• mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis).• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene topical treatment are insufficient.fluconazole is indicated in adults for the prophylaxis of:• relapse of cryptococcal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving haematopoetic stem cell transplantation ).fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old:fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - concentrate for dispersion for injection - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines - comirnaty is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 virus, in individuals 12 years of age and older.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - concentrate for dispersion for injection - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines - comirnaty is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 virus, in individuals 12 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium metabisulfite; phenol; water for injections; sulfuric acid; disodium edetate - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should be instituted.,note that bacterial cultures should bo obtained before and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. if the organisms are resistant, other appropriate therapy should be instituted. in patients in whom gram-negative septicaemia, neonatal sepsis or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cefalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, the severity of infection and the important additional concepts discussed in the product information leaflet.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tobramycin, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; disodium edetate; sodium hydroxide; sulfuric acid - for the treatment of serious infections of the following type where they are caused by susceptible organisms: skin and skin structure infections including burns, bone infections; gastrointestinal infections including peritonitis; central nervous system infections including meningitis, septicaemia and neonatal sepsis; lower respiratory tract infections including pneumonia, bronchopneumonia, and acute bronchitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis.,aminoglycosides, including tobramycin, should not be used in uncomplicated initial episodes of urinary tract infection unless the causative organisms are not susceptible to other less toxic antibiotics.,tobramycin can be used in serious staphylococcal infections for which penicillin or other less toxic drugs are contraindicated and where susceptibility testing and clinical judgement indicate its use. if susceptibility tests show a resistance to tobramycin in the causative organisms other appropriate therapy should

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline;  ;   - film coated tablet - 0.5 mg - active: varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry clear ys-2-19114-a opadry white ys-1-18202 - an aid to smoking cessation

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - varenicline tartrate 1.71mg equivalent to 1 mg varenicline;  ;   - film coated tablet - 1 mg - active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline;  ;  ; varenicline tartrate 1.71mg equivalent to 1 mg varenicline - combination - 0.5 mg and 1 mg - active: varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry clear ys-2-19114-a opadry white ys-1-18202 active: varenicline tartrate 1.71mg equivalent to 1 mg varenicline excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 03b90547 opadry clear ys-2-19114-a - an aid to smoking cessation

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.);  ; medroxyprogesterone acetate 2.6mg (includes 4% overage.); conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.); medroxyprogesterone acetate 2.6mg (includes 4% overage.) - tablet - active: conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.)   medroxyprogesterone acetate 2.6mg (includes 4% overage.) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose   opacode black s-8-27741 povidone shellac stearic acid sucrose     titanium dioxide   active: conjugated estrogens 0.625mg (15mg as a dessication with lactose, includes 3% overage.) medroxyprogesterone acetate 2.6mg (includes 4% overage.) excipient: calcium sulfate carnauba wax glyceryl mono-oleate iron oxide red lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode black s-8-27741 povidone shellac stearic acid sucrose titanium dioxide